SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.

Westwood, M; Bourbeau, J; Jones, PW; Cerulli, A; Capkun-Niggli, G; Worthy, G (2011) Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. RESPIRATORY RESEARCH, 12 (40). ISSN 1465-993X https://doi.org/10.1186/1465-9921-12-40
SGUL Authors: Jones, Paul Wyatt

[img]
Preview
PDF Published Version
Download (594kB) | Preview

Abstract

BACKGROUND: Interactions between spirometry and patient-reported outcomes in COPD are not well understood. This systematic review and study-level analysis investigated the relationship between changes in FEV1 and changes in health status with bronchodilator therapy. METHODS: Six databases (to October 2009) were searched to identify studies with long-acting bronchodilator therapy reporting FEV1 and health status, dyspnoea or exacerbations. Mean and standard deviations of treatment effects were extracted for each arm of each study. Relationships between changes in trough FEV1 and outcomes were assessed using correlations and random-effects regression modelling. The primary outcome was St George's Respiratory Questionnaire (SGRQ) total score. RESULTS: Thirty-six studies (≥ 3 months) were included. Twenty-two studies (23,654 patients) with 49 treatment arms each contributing one data point provided SGRQ data. Change in trough FEV1 and change in SGRQ total score were negatively correlated (r = -0.46, p < 0.001); greater increases in FEV1 were associated with greater reductions (improvements) in SGRQ. The correlation strengthened with increasing study duration from 3 to 12 months. Regression modelling indicated that 100 mL increase in FEV1 (change at which patients are more likely to report improvement) was associated with a statistically significant reduction in SGRQ of 2.5 (95% CI 1.9, 3.1), while a clinically relevant SGRQ change (4.0) was associated with 160.6 (95% CI 129.0, 211.6) mL increase in FEV1. The association between change in FEV1 and other patient-reported outcomes was generally weak. CONCLUSIONS: Our analyses indicate, at a study level, that improvement in mean trough FEV1 is associated with proportional improvements in health status.

Item Type: Article
Additional Information: PubMed ID: 21477298 © 2011 Westwood et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Administration, Inhalation, Aged, Bronchodilator Agents, Evidence-Based Medicine, Female, Forced Expiratory Volume, Health Status, Health Status Indicators, Humans, Linear Models, Lung, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive, Randomized Controlled Trials as Topic, Spirometry, Time Factors, Treatment Outcome, Science & Technology, Life Sciences & Biomedicine, Respiratory System, OBSTRUCTIVE PULMONARY-DISEASE, FORMOTEROL DRY POWDER, ONCE-DAILY TIOTROPIUM, METERED-DOSE INHALER, QUALITY-OF-LIFE, HEALTH-STATUS, SPIROMETRIC EFFICACY, IPRATROPIUM BROMIDE, CLINICAL-TRIAL, AIR-FLOW
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: RESPIRATORY RESEARCH
ISSN: 1465-993X
Related URLs:
Dates:
DateEvent
8 April 2011Published
Web of Science ID: WOS:000290405900001
Download EPMC Full text (PDF)
Download EPMC Full text (HTML)
URI: http://openaccess.sgul.ac.uk/id/eprint/641
Publisher's version: https://doi.org/10.1186/1465-9921-12-40

Actions (login required)

Edit Item Edit Item